Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS (ALXN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Alexion Pharmaceuticals : Agrees to Work With Hedge Fund Elliott on Filling Board Seat--Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/03/2018 | 01:08am CET
By Aisha Al-Muslim 

Alexion Pharmaceuticals Inc. said Tuesday it will work with hedge fund Elliott Management Corp. on filling an open board seat.

The move comes as the rare-disease drugmaker has been facing pressure from the activist investor, which has pushed for changes in recent years at companies including aluminum parts maker Arconic Inc. and Brocade Communication Systems, now part of Broadcom Ltd.

The agreement between the board and Elliott is part of efforts to "maintain active and constructive dialogue with all of our shareholders, " Alexion Board Chairman David Brennan said in prepared remarks.

The New York Times reported last month, citing two unnamed sources, that Elliott had built a stake in Alexion and urged the company to make changes to lift its stock price.

Alexion said in November that it was searching for a candidate to fill a seat on its board, which currently has 11 members.

The company and Elliott declined to comment Tuesday on the size of Elliott's stake in the firm.

The New Haven, Conn., drugmaker, founded in 1992, has had many management changes during the past year, including hiring Chief Executive Ludwig Hantson in March, after an internal investigation showed senior management pressured staff to persuade customers to order its flagship drug earlier than needed to meet financial targets.

The company's primary product is a rare blood-disease treatment named Soliris.

Under Mr. Hantson's leadership, much of the senior management team was replaced. Alexion in September said it was cutting its workforce by 20%, relocating its headquarters to Boston and closing sites as it works to reduce its overhead. The moves were expected to create $250 million in annual cost savings by 2019.

"We are encouraged by actions taken under Ludwig's leadership to improve financial performance and reset Alexion's strategy," an Elliott spokesperson said in prepared remarks.

Shares in Alexion, down nearly 12% in the past three months, were unchanged at $124.05 in after-hours trading Tuesday. Alexion had a stock market value of $27.71 billion as of market close.

Write to Aisha Al-Muslim at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALEXION PHARMACEUTICALS
01/18 ALEXION PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2017 Results on..
01/04 ALEXION PHARMACEUTICALS : to Present at the 36th Annual J.P. Morgan Healthcare C..
01/04 ALEXION PHARMACEUTICALS : and Elliott Agree To Collaborate On Identifying a New ..
01/03 ALEXION PHARMACEUTICALS : Agrees to Work With Hedge Fund Elliott on Filling Boar..
01/03 ALEXION PHARMACEUTICALS : Agrees to Work With Hedge Fund Elliott on Filling Boar..
01/02 ALEXION PHARMACEUTICALS : and Elliott Agree to Collaborate on Identifying a New ..
01/02 ALEXION PHARMACEUTICALS : to Present at the 36th Annual J.P. Morgan Healthcare C..
2017 ALEXION PHARMACEUTICALS : Soliris Receives Marketing Authorization in Japan for ..
2017 ALEXION PHARMACEUTICALS : Wired News - Alexion Announced Marketing Authorization..
2017 ALEXION PHARMACEUTICALS : Soliris® (Eculizumab) Receives Marketing Authorization..
More news
News from SeekingAlpha
01/10 CELGENE : Parsing Through The $7 Billion Impact Acquisition
01/09 Alexion Pharmaceuticals (ALXN) Presents At 36th Annual J.P. Morgan Healthcare..
01/09 ACHILLION PHARMACEUTICALS : Ultra-Rare Disease Company With Ultra-Rare Enterpris..
01/08 OMEROS CORPORATION : A Valuation
01/08 Valuation Dashboard In Healthcare - New Year's Update
Financials ($)
Sales 2017 3 520 M
EBIT 2017 1 474 M
Net income 2017 547 M
Debt 2017 1 224 M
Yield 2017 -
P/E ratio 2017 49,10
P/E ratio 2018 26,81
EV / Sales 2017 7,99x
EV / Sales 2018 6,56x
Capitalization 26 887 M
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 160 $
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Julie O'Neill Executive Vice President-Global Operations
Paul J. Clancy Chief Financial Officer
John J. Orloff Executive VP & Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS4.09%26 887
BIOGEN6.37%72 841
CSL LIMITED0.51%51 316
GRIFOLS SA6.73%19 751
BIOMARIN PHARMACEUTICAL1.20%15 767
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%8 324